Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
RedHill Biopharma Ltd. RDHL
$2.29
-$0.02 (-0.71%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
6960277.00000000
-
week52high
49.20
-
week52low
2.05
-
Revenue
61800000
-
P/E TTM
0
-
Beta
2.16262900
-
EPS
-45.23000000
-
Last Dividend
0.00000000
-
Next Earnings Date
21 июн 2023 г. в 12:30
Описание компании
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 15 сент 2021 г. |
| Cantor Fitzgerald | Overweight | 31 авг 2021 г. | |
| WBB Securities | Buy | Strong Buy | 28 мая 2021 г. |
| HC Wainwright & Co. | Buy | 18 мая 2021 г. | |
| BTIG | Buy | 11 сент 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
The Impact of Market Trends on Penny Stocks Performance
PennyStocks
28 янв 2023 г. в 06:00
Understand how market trends impact penny stocks The post The Impact of Market Trends on Penny Stocks Performance appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Redhill Biopharma (RDHL) Stock Up 32% Today?
InvestorPlace
27 янв 2023 г. в 07:46
Redhill Biopharma (NASDAQ: RDHL ) stock is rocketing higher on Friday after getting positive patent news from the U.S. Patent and Trademark Office (USPTO). The USPTO issued a Notice of Allowance that grants the company a patent for RHB-204's treatment methods.
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
Zacks Investment Research
20 окт 2022 г. в 14:18
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
3 Strategies for Buying and Selling Penny Stocks Right Now
PennyStocks
20 окт 2022 г. в 06:00
Can these penny stocks trading tips help your strategy? The post 3 Strategies for Buying and Selling Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What Is Going on With Redhill Biopharma (RDHL) Stock Today?
InvestorPlace
19 окт 2022 г. в 11:06
Redhill Biopharma (NASDAQ: RDHL ) stock is rocketing higher on Wednesday after the company received a patent for one of its oral antiviral treatments. That patent covers the administration of opaganib.